(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Recruiting · NCT04996875 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Soft Tissue Neoplasms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, connective tissue disorder, connective tissue neoplasm, cutaneous mastocytosis, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, leukemia, maculopapular cutaneous mastocytosis, mast cell leukemia, mastocytosis, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, skin disorder, skin neoplasm, skin pigmentation disorder, type III hypersensitivity disease | Recruiting | Phase 2 | 2026-09-15 | NCT04996875 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cogent Biosciences, Inc. | 7 |
42 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.